Ryan Scott is an Editor of CURE; she joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages CURE's social media accounts; check us out ...
RP2D zovegalisib 600 mg BID plus fulvestrant yielded ORR 38.7% (31 evaluable) and tumor reduction in 80.6%, supporting mutant-selective PI3Kα targeting after endocrine resistance. Antitumor activity ...
What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results